This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

Moderna Inc MRNA shares are rising in Tuesday’s after-hours session after the company announced it reached a settlement agreement with Arbutus Biopharma and Genevant Sciences. Moderna shares are ...

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak.

Moderna has outperformed the Dow over the past year, yet Wall Street analysts maintain a cautious outlook on the stock’s ...

Moderna (MRNA) stock rises as a $950M payment to resolve a patent dispute with Arbutus (ABUS) and Roivant (ROIV) lifts a key legal overhang. Read more here.

Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today’s Market Action. Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after ...

Moderna (MRNA) stock is on the rise after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based ...

Shares of Moderna MRNA rose about 4% on Friday after the company announced that the EMA’s Committee for Medicinal Products ...